0001213900-25-104686
SEC filingThe provided section covers major shareholders and related party transactions, not MD&A performance discussion.
The document content provided is Item 7 on Major Shareholders and Related Party Transactions, which does not contain the Management's Discussion and Analysis of financial condition and results of operations. Therefore, no MD&A analysis can be performed based on this input.
As of June 30, 2025, Regencell held $2.4 million in cash and $2.5 million in short-term investments, totaling $4.9 million in liquid assets. Total assets were $5.8 million, with no debt (total liabilities of $0.9 million primarily from accrued expenses and lease liabilities). Shareholders' equity stood at $4.9 million. The company has a significant accumulated deficit of $25.2 million. The independent auditor's report includes a going concern explanatory paragraph due to recurring losses and operating cash outflows.
No purchase commitments, supply agreements, or material contractual obligations are disclosed in the provided Notes section. The company has operating lease liabilities of $0.5 million (current $0.3 million, non-current $0.2 million). No other commitments were identified.
The company states it intends to retain earnings for business expansion and does not anticipate paying dividends. There are no share buyback programs or debt issuances. Capital expenditures were $0.15 million in fiscal 2025, primarily for property and equipment. No share repurchases occurred.
No segment reporting is provided as the company operates as a single early-stage bioscience entity. All operations are conducted through Hong Kong subsidiaries, and revenue has not yet been generated. The Notes do not break out geographic or product-level financials.
The provided document excerpt includes the auditor's report, balance sheets, and income statements, but does not include the Consolidated Statements of Cash Flows (referenced as F-6). Without the cash flow statement, no analysis of operating, investing, or financing cash flows, capital expenditures, or free cash flow is possible. The financial statements appear to be from Regencell Bioscience Holdings Limited for fiscal years ended June 30, 2025, 2024, and 2023, but the cash flow details are missing. Please provide the cash flow statement excerpt for further analysis.